Dr. Karen Keyse Fields, MD

  • Houston, TX
  • Hematologist and oncologist
NPI1659423697
Part D claims, 2020
12
Publications
56
Clinical trials
2
Industry payments
$16,197
Insurance carriers
1
Practice address
1515 Holcombe Blvd, Houston, TX 77030-4009
Practice phone
Call (713) 792-6161
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Find Dr. Fields' professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Karen Keyse Fields is a hematologist and oncologist in Houston, Texas

Dr. Fields practices in Houston, Texas.

Dr. Fields' NPI, 1659423697, was assigned on January 18, 2007. Dr. Fields graduated from Ohio State College of Medicine in 1981. Dr. Fields holds Texas license 41730.

NPI and contact details
NPI enumeration date
January 18, 2007
NPI status
Active
Practice phone
(713) 792-6161
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Female
Estimated age
71
Medical school graduation
1981

Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data

Dr. Karen Keyse Fields' practice address is in Houston, Texas

Dr. Fields' practice address in the NPI Registry is 1515 Holcombe Blvd, Houston, TX 77030-4009. The practice phone is (713) 792-6161.

  • NPI Registry address
    1515 Holcombe Blvd, Houston, TX 77030-4009Phone(713) 792-6161

Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data

Dmand AI tracks the EHR system at Dr. Karen Keyse Fields' practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fields practices. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Dr. Fields' practiceAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every site where Dr. Fields practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Karen Keyse Fields is one of 814 hematologists and oncologists in Texas

Hematology and oncology is Dr. Fields' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Fields' licenses on file in 4 states: Texas, Florida, Ohio and Nevada.

Specialties and state licenses

  • Hematology and oncology, TexasPrimaryLicense 41730 · taxonomy 207RH0003X
  • Florida license1988 to 2023
  • Ohio license1984 to 2023
  • Nevada license2009 to 2013

Hematologists and oncologists near Dr. Fields

Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Karen Keyse Fields' patients have a median age of 67

Across all payers, Dmand AI patient panel data puts Dr. Fields' median patient age at 67, with 100% women.

Dr. Fields' patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 67

Patient panel by sex, all payers

  • Women100%
  • Men0%

Source: Dmand AI Patient Panel Data

Dr. Karen Keyse Fields wrote 12 Medicare Part D claims in 2020

In 2020, Dr. Fields wrote 12 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $191 in total drug cost. In 2019, CMS named 17 claims across 1 drug.

Part D claims, 202012
Drugs named by CMS1
Total drug cost$191

Dr. Fields' most prescribed drugs by claims, 2020

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Part D claims for drugs CMS names, 2019 to 2020

  • 2019
  • 2020
Claims for drugs CMS names
2019: 172020: 1229%

Drugs named by CMS: 1 in 2020, 1 in 2019.

See all prescribing by Dr. Fields

Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026

For MedTech and pharma teams

Find hematologists and oncologists like Dr. Fields by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Karen Keyse Fields has 56 publications on record

Dmand AI links 56 papers to Dr. Fields, published from 2011 to 2021. 2011 was the busiest year, with 2. The most frequent topics are Hematopoietic Stem Cell Transplantation, Breast Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Fields has published most often in Bone Marrow Transplant. Dr. Fields' most frequent co-authors are John William Hiemenz, MD, Paul Edward Zorsky, MD and Long Jin, MD.

Papers56
Years published2011 to 2021

Topics Dr. Fields writes about most

  • Hematopoietic Stem Cell Transplantation
  • Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow Transplantation
  • Etoposide
  • Ifosfamide
  • Transplantation, Autologous
  • Carboplatin

Dr. Fields' most frequent co-authors

Recent publications by Dr. Fields

See all 56 publications and co-authors

See who Dr. Fields researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Fields works with, so you can find a warm path to the right hematologists and oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Karen Keyse Fields has worked on 2 clinical trials

Dmand AI links Dr. Fields to 2 clinical trials. Conditions studied include Breast Neoplasms, Carcinoma, Ovarian Epithelial and Breast Diseases. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

Clinical trials with Dr. Fields by phase

  1. NonePhase 1: no trials
  2. 1Phase 1/2: 1 trial
  3. 1Phase 2: 1 trial
  4. NonePhase 3: no trials
  5. NonePhase 4: no trials

Conditions in Dr. Fields' trials

  • Breast Neoplasms
  • Carcinoma, Ovarian Epithelial
  • Breast Diseases
  • Ovarian Neoplasms

Recent clinical trials with Dr. Fields

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Karen Keyse Fields received $16,197 in industry payments from 2016 to 2018

CMS Open Payments shows 21 general payments to Dr. Fields from 5 drug and device companies from 2016 to 2018. Consulting fees make up the largest share, 34% of the total. Pfizer Inc. paid the most, $5,877.

General payments to Dr. Fields by program year, 2016 to 2018

General payments to Dr. Fields by kind, 2016 to 2018

$16.2Kin total
  • Consulting fees$5,50034%
  • Honoraria$4,66529%
  • Travel and lodging$3,53222%
  • Speaker and faculty fees$2,00012%
  • Food and beverage$5003%

Companies that paid Dr. Fields the most, 2016 to 2018

Share is of all general payments to this clinician.

See all payments to Dr. Fields

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Karen Keyse Fields graduated from Ohio State College of Medicine

Dr. Fields graduated from Ohio State College of Medicine in 1981.

  1. Medical schoolOhio State College of Medicine

Source: Dmand AI Professional Profile Data

Dr. Karen Keyse Fields accepts plans from 1 insurance carrier

Dr. Fields is in network with 1 carrier, including Molina. HMO plans come from the most carriers, 1. Check the plan with the practice before a visit.

  • Molina

Plan types Dr. Fields accepts, by number of carriers

  1. HMO1
  2. Medicare1

Source: Dmand AI Insurance Network Data

Sources for Dr. Karen Keyse Fields's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data
Medicare patients and the all-payer patient panelDmand AI Patient Panel Data
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
Insurance carriers and plan typesDmand AI Insurance Network Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Karen Keyse Fields

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Karen Keyse Fields' NPI number?

Dr. Karen Keyse Fields' NPI number is 1659423697. It was assigned on January 18, 2007, and it is active in the NPI Registry.

What kind of doctor is Dr. Karen Keyse Fields?

Dr. Karen Keyse Fields is a hematologist and oncologist in Houston, Texas. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).

Where does Dr. Karen Keyse Fields practice?

Dr. Fields practices at 1515 Holcombe Blvd, Houston, TX 77030-4009.

What is Dr. Karen Keyse Fields' office phone number?

The practice phone on file for Dr. Fields is (713) 792-6161.

What is Dr. Karen Keyse Fields' medical license number?

Dr. Fields holds Texas license 41730, one of the licenses on file in 4 states.

Which states has Dr. Karen Keyse Fields been licensed in?

Dmand AI has state licenses on file for Dr. Fields in Texas, Florida (1988 to 2023), Ohio (1984 to 2023) and Nevada (2009 to 2013).

Where did Dr. Karen Keyse Fields go to medical school?

Dr. Fields graduated from Ohio State College of Medicine in 1981.

What drugs does Dr. Karen Keyse Fields prescribe most?

In 2020 Medicare Part D data, Dr. Fields' most prescribed drugs by claims were Tamoxifen Citrate.

Has Dr. Karen Keyse Fields received payments from drug or device companies?

CMS Open Payments shows $16,197 in general payments to Dr. Fields from 5 companies from 2016 to 2018. The largest total came from Pfizer Inc.

How long has Dr. Karen Keyse Fields been practicing?

Dr. Fields graduated from medical school in 1981, 45 years ago.

Show 3 more questionsShow fewer questions

Does Dr. Karen Keyse Fields do research?

Dmand AI links 56 publications to Dr. Fields, published from 2011 to 2021. Dr. Fields has worked on 2 clinical trials.

Who does Dr. Karen Keyse Fields publish with?

Dr. Fields' most frequent co-authors are John William Hiemenz, MD (9 shared papers), Paul Edward Zorsky, MD (9 shared papers) and Long Jin, MD (8 shared papers).

What insurance does Dr. Karen Keyse Fields accept?

Dr. Fields is in network with 1 carrier, including Molina. HMO plans come from the most carriers, 1. Check the plan with the practice before a visit.

Selling to hematology and oncology practices?

See hematologists and oncologists in Texas by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)